Spasticity Pipeline Appears Promising With 10+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment | DelveInsight

DelveInsight's, "Spasticity Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Spasticity pipeline landscape. It covers the Spasticity pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Spasticity pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight's comprehensive Spasticity Pipeline Report to explore emerging therapies, key Spasticity Companies, and future Spasticity treatment landscapes @ Spasticity Pipeline Outlook Report- https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Spasticity Pipeline Report
• In July 2025, Celgene announced a Phase 2 study assessing the Efficacy, Safety and Tolerability of Three Doses of Orally Administered BMS-986368, a FAAH/MAGL Inhibitor, for the Treatment of Spasticity in Participants With Multiple Sclerosis (BALANCE-MSS-1).
• In June 2025, Ipsen conducted a study is to assess the safety and efficacy of increasing doses of IPN10200 with the aim to evaluate the Pharmacodynamics (PD) profile of IPN10200 and to establish the total IPN10200 doses(s) that offer the best efficacy/safety profile when used for the treatment of Adult upper limb (AUL) spasticity.
• DelveInsight's Spasticity pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Spasticity treatment.
• The leading Spasticity Companies such as Elpida Therapeutics SPC, Saol Therapeutics, Revance Therapeutics Inc., BlackfinBio Ltd, Ipsen, Motor Pharma, Lundbeck A/S and others.
• Promising Spasticity Pipeline Therapies such as IPN10200, SL-1002, Botulinum toxin type A, SPARC0921, Tizanidine, Moxifloxacin, Ultrasonography guidance injection of Meditoxin® and others.

Discover how the Spasticity treatment paradigm is evolving. Access DelveInsight's in-depth Spasticity Pipeline Analysis for a closer look at promising breakthroughs @ Spasticity Clinical Trials and Studies- https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Spasticity Emerging Drugs Profile
• MELPIDA : Elpida Therapeutics SPC
Elpida Therapeutics SPC is a Social Purpose Corporation dedicated to developing gene therapies for ultra-rare pediatric diseases. Founded by Terry Pirovolakis after his son was diagnosed with SPG50, Elpida aims to bring hope (""Elpida"" means ""hope"" in Greek) to families affected by such conditions. Their lead candidate, Melpida (short for ""Michael's Hope""), is an AAV9-based gene therapy designed to treat SPG50 by delivering a functional AP4M1 gene via intrathecal injection. Melpida has progressed through Phase I/II trials and received FDA approval to initiate a Phase III study involving eight children, set to begin in August 2024. Elpida's mission extends beyond SPG50, with plans to advance additional gene therapy programs targeting other ultra-rare diseases, such as Charcot-Marie-Tooth disease type 4J (CMT4J). By focusing on scalable and socially responsible approaches, Elpida strives to make transformative treatments accessible to children worldwide. The drug is currently under Phase III of development.

• SIL 1002: Saol Therapeutics
SL-1002 is a novel, proprietary chemoneurolytic injection currently under investigation for treating limb spasticity and pain related to knee osteoarthritis in adults (18+) in the United States. Currently, the drug is in the Phase II stage of development for clinical trial evaluation for the treatment of spasticity.

• IPN-10200: Ipsen
IPN-10200 is Ipsen's investigational longer-acting botulinum neurotoxin type A (mrBoNT/A), designed to provide extended therapeutic effects compared to existing treatments. Administered intramuscularly, it is currently undergoing Phase I/II clinical trials for both aesthetic and therapeutic indications. These include moderate to severe upper facial lines-such as glabellar, forehead, and lateral canthal lines-and adult upper limb spasticity resulting from stroke or traumatic brain injury. The ongoing studies aim to evaluate its safety, efficacy, and optimal dosing, with the goal of offering patients longer-lasting symptom relief and fewer treatment sessions. Currently, the drug is in the Phase I/II stage of development for clinical trial evaluation for the treatment of spasticity.

The Spasticity pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Spasticity with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spasticity Treatment.
• Spasticity Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Spasticity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Spasticity market.

Get a detailed analysis of the latest innovations in the Spasticity pipeline. Explore DelveInsight's expert-driven report today! @ Spasticity Unmet Needs- https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Spasticity Companies
Elpida Therapeutics SPC, Saol Therapeutics, Revance Therapeutics Inc., BlackfinBio Ltd, Ipsen, Motor Pharma, Lundbeck A/S and others.

Spasticity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Spasticity Products have been categorized under various Molecule types such as
• Monoclonal antibody
• Small molecule
• Peptide

Download DelveInsight's latest report to gain strategic insights into upcoming Spasticity Therapies and key Spasticity Developments @ Spasticity Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Spasticity Pipeline Report
• Coverage- Global
• Spasticity Companies- Elpida Therapeutics SPC, Saol Therapeutics, Revance Therapeutics Inc., BlackfinBio Ltd, Ipsen, Motor Pharma, Lundbeck A/S and others.
• Spasticity Pipeline Therapies- IPN10200, SL-1002, Botulinum toxin type A, SPARC0921, Tizanidine, Moxifloxacin, Ultrasonography guidance injection of Meditoxin® and others.
• Spasticity Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Spasticity Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Spasticity drug development? Find out in DelveInsight's exclusive Spasticity Pipeline Report-access it now! @ Spasticity Emerging Drugs and Major Companies- https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Spasticity: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Spasticity- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. MELPIDA: Elpida Therapeutics SPC
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. SIL 1002: Saol Therapeutics
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I/II)
14. IPN-10200: Ipsen
15. Drug profiles in the detailed report.....
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report.....
19. Inactive Products
20. Spasticity Key Companies
21. Spasticity Key Products
22. Spasticity- Unmet Needs
23. Spasticity- Market Drivers and Barriers
24. Spasticity- Future Perspectives and Conclusion
25. Spasticity Analyst Views
26. Spasticity Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.